Basilea is halfway through its US development plans for Zevtera after recently reporting positive “TARGET” pivotal trial results in skin infections. Results of the second cross-supportive “ERADICATE” pivotal trial in bacteremia are expected in H2 2021. Peak sales for both new Zevtera indications could amount to more than CHF 300 mn and trigger a lucrative partnering deal. Cresemba reported strong sales growth in H1 2019, which is expected to continue. Profitability should be approached in 2020/2021 with sufficient cash, external funding (e.g. BARDA) and revenues from Cresemba and Zevtera to develop the key pipeline projects up to their next value inflection points.
Key catalysts include
- Results POC trial of BAL101553 in brain & ovarian cancer (end 2019)
- Interim data derazantinib/Tecentriq POC trial in urothelial cancer (H2 2020)
- Results registrational trial of derazantinib in iCCA (H2 2020)